Back to News
Market Impact: 0.3
DataMEDS AI Buys Helomics Cancer Lab And CRO Assets As Shares Jump 170% In Pre-Market
Source: Nasdaq
M&A & RestructuringArtificial IntelligenceHealthcare & BiotechTechnology & Innovation
DataMEDS AI (MEDS) acquired Helomics AI's cancer diagnostics laboratory and precision-oncology contract research businesses from Axe Compute (AGPU). The transaction expands DataMEDS' presence in AI-driven precision medicine and oncology diagnostics, although no transaction value or financial terms were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AGPU0.15
MEDS0.60
More News
- 'Hostile act': Trump threatens EU with tariffs over Canada associate-membership proposal
- US official says upcoming spectrum auctions could generate more than $100 billion
- Investors react to Fed hike and market sell-off: Brace for 'higher for longer' rates
- Fed delivers its first hike in 3 years. Plus, what's moving Starbucks and GE Vernova
- Fed’s Warsh lays out forces driving up bond yields
- The Fed unanimously agrees to hike interest rates for the first time since 2023, despite Trump’s call for the ‘lowest rates’ in the world
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate Consensus Estimates Platforms With AI
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More